Inactive Instrument

InspireMD Inc Stock NYSE

US45779A3095

Medical Equipment, Supplies & Distribution

End-of-day quote NYSE
- ^USD	-

08-17	InspireMD, Inc., Q2 2026 Earnings Call, Aug 17, 2026
08-14	InspireMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Last Transcript: InspireMD Inc

InspireMD, Inc., Q2 2026 Earnings Call, Aug 17, 2026

08-17

More transcripts

Analysts' recommendations: InspireMD Inc

23-06-12	Piper Sandler Initiates InspireMD at Overweight With $3 Price Target	MT
23-05-17	Alliance Global Adjusts Price Target on InspireMD to $4.75 From $5.15, Maintains Buy Rating	MT

More recommendations

Managers and Directors: InspireMD Inc

Manager	Title	Age	Since
Marvin Slosman CEO	Chief Executive Officer	62	2019-12-31
Michael Lawless DFI	Director of Finance/CFO	58	2025-06-24
Shany Barel CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Stuka CHM	Chairman	71	2017-06-01
Michael Berman BRD	Director/Board Member	68	2013-02-06
Marvin Slosman BRD	Director/Board Member	62	2019-12-31

More insiders

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	41.83M 35.83M 33.53M 30.69M 57.6M 4B 58.36M 396M 154M 2.01B 157M 154M 6.65B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	41.83M 35.83M 33.53M 30.69M 57.6M 4B 58.36M 396M 154M 2.01B 157M 154M 6.65B	EV / Sales 2026 *	4.27x	EV / Sales 2027 *	2.08x
Free-Float	80.03%	Yield 2026 *	-	Yield 2027 *	-

08-17	InspireMD, Inc., Q2 2026 Earnings Call, Aug 17, 2026
08-14	InspireMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-29	InspireMD, Inc. Appoints Kathleen Kennedy as Senior Vice President of Global Sales and Marketing	CI
07-29	InspireMD, Inc. Announces Elimination of Shane Gleason as Chief Commercial Officer, Effective July 31, 2026	CI
07-24	InspireMD Receives Nasdaq Minimum Bid Price Warning	MT
07-02	InspireMD, Inc. Announces Resignation of Raymond W. Cohen from Board and Committees, Effective July 1, 2026	CI
06-29	InspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell 3000E Growth Benchmark	CI
06-28	InspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell Microcap Growth Benchmark Index	CI
06-19	InspireMD, Inc. Announces Recalling Action on CGuard Prime Carotid Stent System 135Cm, 10Mmx30mm	CI
06-19	InspireMD, Inc. Announces Recalling Action for CGuard Prime Carotid Stent System 135cm, 10mmx40mm	CI
06-19	Inspiremd Inc Announces Recalling Action on Cguard Prime Carotid Stent System 135cm, 9mx30mm	CI
06-19	InspireMD, Inc. Announces Recalling of Cguard Prime Carotid Stent System 135Cm, 8Mmx30mm	CI
06-19	InspireMD Inc Announces Recalling Action For CGuard Prime Carotid Stent System 135cm, 8mmx40mm	CI

08-17	InspireMD Reports Second Quarter 2026 Financial Results	AQ
08-10	InspireMD to Announce Second Quarter 2026 Financial Results	AQ
08-07	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
07-30	InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing	AQ
06-15	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STRYKER CORPORATION	+0.53%	-2.88%	-16.43%	+19.38%	126B
SMITH & NEPHEW PLC	-0.23%	-1.75%	-22.54%	+0.75%	12.26B
GLAUKOS CORPORATION	0.00%	+0.20%	+96.38%	+146.55%	10.9B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-4.90%	-8.39%	-52.04%	-68.46%	4.14B
DOUBLE MEDICAL TECHNOLOGY INC.	-0.43%	-1.43%	-24.31%	+52.19%	2.69B
INSPIRE MEDICAL SYSTEMS, INC.	+1.78%	+9.21%	-35.03%	-70.48%	1.8B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-1.13%	-0.43%	-23.65%	-11.22%	1.66B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-3.68%	-3.53%	-35.52%	-37.91%	1.61B
Average	-1.01%	-0.61%	-14.14%	+3.85%	20.18B
Weighted average by Cap.	+0.23%	-2.52%	-10.79%	+22.96%

	2026 *	2027 *
Net sales	9.8M 8.39M 7.85M 7.19M 13.49M 938M 13.67M 92.79M 36.19M 471M 36.8M 35.99M 1.56B	20.13M 17.25M 16.14M 14.77M 27.72M 1.93B 28.09M 191M 74.34M 968M 75.59M 73.95M 3.2B
Net income	-	-
Net Debt	-	-

InspireMD Inc Stock NYSE

Stocks

US45779A3095

Medical Equipment, Supplies & Distribution

Valuation: InspireMD Inc

Latest news : InspireMD Inc

Last Transcript: InspireMD Inc

Analysts' recommendations: InspireMD Inc

Press Releases: InspireMD Inc

Managers and Directors: InspireMD Inc

Medical Devices & Implants

Financials

Company Profile